IgE Plasma Cell Leukemia Harboring t(11;14) and 1q Amplification
IgE plasma cell neoplasm is the rarest subtype of plasma cell neoplasms and is known for its poor prognosis and high incidence of t(11;14). However, t(11;14) has been classified as a standard-risk rather than high-risk cytogenetic abnormality in multiple myeloma. We have been unable to explain the d...
Saved in:
| Main Authors: | , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2023-01-01
|
| Series: | Case Reports in Hematology |
| Online Access: | http://dx.doi.org/10.1155/2023/4747989 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832547944596766720 |
|---|---|
| author | Wataru Nakahara Takahito Ogawa Hitomi Matsunaga Yuki Iwasa Momoka Horita Mako Ikeda Mizuki Asako Sadaharu Iio Yuki Iwama Kazumasa Oka Shuji Ueda |
| author_facet | Wataru Nakahara Takahito Ogawa Hitomi Matsunaga Yuki Iwasa Momoka Horita Mako Ikeda Mizuki Asako Sadaharu Iio Yuki Iwama Kazumasa Oka Shuji Ueda |
| author_sort | Wataru Nakahara |
| collection | DOAJ |
| description | IgE plasma cell neoplasm is the rarest subtype of plasma cell neoplasms and is known for its poor prognosis and high incidence of t(11;14). However, t(11;14) has been classified as a standard-risk rather than high-risk cytogenetic abnormality in multiple myeloma. We have been unable to explain the discrepancy that the hallmark of IgE plasma cell neoplasm with a poor prognosis is a standard-risk cytogenetic abnormality. Here, we report a case of IgE primary plasma cell leukemia with extramedullary lesions of the liver, stomach, and lymph nodes. Plasma cell infiltration was pathologically confirmed in each organ. Cytogenetic analysis of plasma cells revealed t(11;14) and amplification of 1q21. Chemotherapy, with immunomodulatory imide drugs, proteasome inhibitors, and CD38 antibodies, was unsuccessful. In IgE plasma cell neoplasm, coexistence of other cytogenetic abnormalities with t(11;14) may be important. Investigating the presence of cytogenetic abnormalities coexisting with t(11;14) is not only useful for evaluating prognosis but also important for understanding the pathogenesis of the disease. Recently, venetoclax, an oral BCL2 inhibitor, has demonstrated promising efficacy in plasma cell neoplasm patients harboring t(11;14). Development of an effective venetoclax-based regimen for treating aggressive IgE plasma cell neoplasm with t(11;14) is expected. |
| format | Article |
| id | doaj-art-c21669ca0ef8442d99669a69e1fd9bca |
| institution | Kabale University |
| issn | 2090-6579 |
| language | English |
| publishDate | 2023-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Case Reports in Hematology |
| spelling | doaj-art-c21669ca0ef8442d99669a69e1fd9bca2025-02-03T06:42:56ZengWileyCase Reports in Hematology2090-65792023-01-01202310.1155/2023/4747989IgE Plasma Cell Leukemia Harboring t(11;14) and 1q AmplificationWataru Nakahara0Takahito Ogawa1Hitomi Matsunaga2Yuki Iwasa3Momoka Horita4Mako Ikeda5Mizuki Asako6Sadaharu Iio7Yuki Iwama8Kazumasa Oka9Shuji Ueda10Department of HematologyDepartment of HematologyDepartment of HematologyDepartment of Clinical LaboratoryDepartment of Clinical LaboratoryDepartment of HematologyDepartment of HematologyDepartment of GastroenterologyDepartment of RadiologyDepartment of PathologyDepartment of HematologyIgE plasma cell neoplasm is the rarest subtype of plasma cell neoplasms and is known for its poor prognosis and high incidence of t(11;14). However, t(11;14) has been classified as a standard-risk rather than high-risk cytogenetic abnormality in multiple myeloma. We have been unable to explain the discrepancy that the hallmark of IgE plasma cell neoplasm with a poor prognosis is a standard-risk cytogenetic abnormality. Here, we report a case of IgE primary plasma cell leukemia with extramedullary lesions of the liver, stomach, and lymph nodes. Plasma cell infiltration was pathologically confirmed in each organ. Cytogenetic analysis of plasma cells revealed t(11;14) and amplification of 1q21. Chemotherapy, with immunomodulatory imide drugs, proteasome inhibitors, and CD38 antibodies, was unsuccessful. In IgE plasma cell neoplasm, coexistence of other cytogenetic abnormalities with t(11;14) may be important. Investigating the presence of cytogenetic abnormalities coexisting with t(11;14) is not only useful for evaluating prognosis but also important for understanding the pathogenesis of the disease. Recently, venetoclax, an oral BCL2 inhibitor, has demonstrated promising efficacy in plasma cell neoplasm patients harboring t(11;14). Development of an effective venetoclax-based regimen for treating aggressive IgE plasma cell neoplasm with t(11;14) is expected.http://dx.doi.org/10.1155/2023/4747989 |
| spellingShingle | Wataru Nakahara Takahito Ogawa Hitomi Matsunaga Yuki Iwasa Momoka Horita Mako Ikeda Mizuki Asako Sadaharu Iio Yuki Iwama Kazumasa Oka Shuji Ueda IgE Plasma Cell Leukemia Harboring t(11;14) and 1q Amplification Case Reports in Hematology |
| title | IgE Plasma Cell Leukemia Harboring t(11;14) and 1q Amplification |
| title_full | IgE Plasma Cell Leukemia Harboring t(11;14) and 1q Amplification |
| title_fullStr | IgE Plasma Cell Leukemia Harboring t(11;14) and 1q Amplification |
| title_full_unstemmed | IgE Plasma Cell Leukemia Harboring t(11;14) and 1q Amplification |
| title_short | IgE Plasma Cell Leukemia Harboring t(11;14) and 1q Amplification |
| title_sort | ige plasma cell leukemia harboring t 11 14 and 1q amplification |
| url | http://dx.doi.org/10.1155/2023/4747989 |
| work_keys_str_mv | AT watarunakahara igeplasmacellleukemiaharboringt1114and1qamplification AT takahitoogawa igeplasmacellleukemiaharboringt1114and1qamplification AT hitomimatsunaga igeplasmacellleukemiaharboringt1114and1qamplification AT yukiiwasa igeplasmacellleukemiaharboringt1114and1qamplification AT momokahorita igeplasmacellleukemiaharboringt1114and1qamplification AT makoikeda igeplasmacellleukemiaharboringt1114and1qamplification AT mizukiasako igeplasmacellleukemiaharboringt1114and1qamplification AT sadaharuiio igeplasmacellleukemiaharboringt1114and1qamplification AT yukiiwama igeplasmacellleukemiaharboringt1114and1qamplification AT kazumasaoka igeplasmacellleukemiaharboringt1114and1qamplification AT shujiueda igeplasmacellleukemiaharboringt1114and1qamplification |